Challenges to Trajenta's unlisted patents have expanded further. The number of patents targeted by generic companies increased from 8 to 11. According to the pharmaceutical industry on the 5th, Kukje Pharmaceutical recently requested a passive rights scope confirmation trial for three Trajenta-Duo formulation patents. These three formulation patents were previously outside the scope of patent challenges by generic companies. These include ▲10-1775942, ▲10-1763659, and ▲10-1611314, which expire in April 2029, respectively. Kukje Pharmaceutical found three new cases that were not listed in the Ministry of Food and Drug Safety's patent catalog and took on the challenge.

Challenges to Trajenta and Traje